Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Lorin K Johnson"'
Autor:
Robert L Ferris, Tullia C Bruno, Dan P Zandberg, Lisa A McIlvried, Andre A Martel Matos, Marci L Nilsen, Sebastien Talbot, David N Taggart, Lorin K Johnson, Nicole N Scheff, Mona M Yuan, Megan A Atherton, Fendi Obuekwe, Amin Reza Nikpoor
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 11 (2024)
Background Immune checkpoint inhibitors (ICIs) are becoming the standard of care for recurrent and metastatic cancer. Opioids, the primary treatment for cancer-related pain, are immunosuppressive raising concerns about their potential to interfere wi
Externí odkaz:
https://doaj.org/article/62c796305d4944379fd6f5c90f15eae9
Publikováno v:
The American Journal of Gastroenterology. 98:216-219
Treatment of Ulcerative Colitis With Balsalazide: Response to Editorial by Drs. Farrell and Peppercorn and Letter to the Editor by Dr. Hanauer
Autor:
Ronald Pruitt, David Sales, George Koval, John K Bell, Dennis Riff, Lawrence Wruble, Lorin K Johnson, Douglas S. Levine
Publikováno v:
The American Journal of Gastroenterology. 97:1398-1407
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis
Autor:
Jeff Seilhamer, Amanda E. Goodman, Marion Loughnan, Danielle Cairns, Lorin K. Johnson, Richard Buchta, Adam S. Inglis, Albert Tseng, Kieran F. Scott
Publikováno v:
Protein Expression and Purification. 2:127-135
An active preparation of human phospholipase A2 (PLA2) was made after expression as an insoluble fusion protein in Escherichia coli. The new key elements required for PLA2 isolation were the maintenance of the fusion protein in solution after the ini
Autor:
Lorin K. Johnson, Ira Shafran
Publikováno v:
Current medical research and opinion. 21(8)
This open-label study was conducted as a preliminary assessment of rifaximin (200 mg TID for 16 weeks) for the treatment of active Crohn's disease in patients (n = 29) with symptoms for at least 3 months before screening and a Crohn's Disease Activit
Autor:
Michael Safdi, John S. Hanson, Pamela Doty, Lorin K. Johnson, George Koval, John Johanson, Amanda Cross, Ronald Pruitt, Robert Hardi, Barry Winston, Lawrence Wruble, Dennis Riff
Publikováno v:
The American journal of gastroenterology. 97(12)
Balsalazide is a novel azo-bonded 5-aminosalicylic acid treatment for mild-to-moderate ulcerative colitis. The study objective was to compare symptomatic remission rates with balsalazide and mesalamine while controlling for extent of disease and time
Autor:
Douglas S, Levine, Dennis S, Riff, Ronald, Pruitt, Lawrence, Wruble, George, Koval, David, Sales, John K, Bell, Lorin K, Johnson
Publikováno v:
The American journal of gastroenterology. 97(6)
Balsalazide is a new innovative, mesalamine-containing prodrug that is activated by bacteria in the colon. Balsalazide has been shown previously to be well tolerated and effective in the treatment of acute ulcerative colitis. The aim of this study wa
Autor:
Howard Curtis, Clare T. Atherton, W. A. Stack, Nick J. Wight, John Jones, Lorin K. Johnson, Pamela Doty, Christopher J. Hawkey, Shri Pathmakanthan
Publikováno v:
Gastroenterology. 118:A1224-A1225
Autor:
Amanda J. Cross, John F. Johanson, John S. Hanson, Dennis Riff, Pamela Doty, Ronald E. Pruitt, Lawrence Wruble, Michael Safdi, George Koval, Robert Hardi, Lorin K. Johnson, Barry Winston
Publikováno v:
Gastroenterology. 118:A120-A121
Autor:
Peter Vades, Lorin K. Johnson, Jeffrey J. Seilhamer, Susan Frank, Waldemar Pruzanski, Aldons J. Lusis
Publikováno v:
Phospholipase A2 ISBN: 9781468458077
Mammals are now known to contain at least two distinct classes of phospholipases A2, the progenitors of which can be seen in the venoms of snakes. Mammalian “Type I-” PLA2, synthesized primarily by the pancreas, is also present in smaller amounts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92ca0740460c29ae03ca0f438a51642e
https://doi.org/10.1007/978-1-4684-5805-3_2
https://doi.org/10.1007/978-1-4684-5805-3_2